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OBJECTIVES: to perform economic evaluation of three forms of betahistine in 
patients with vertigo. METHODS: an open-labeled prospective multicenter random-
ized study was performed in 14 out-patient clinics of Russia. The duration of a study 
was 30 days. Patients with vertigo were treated with three forms of betahistine 
(Betaserc, Betaver, Vestibo) in combination with any other medications to the discre-
tion of investigator. The effectiveness criteria were proportion of patients with absence 
of moderate and severe functional disorders (according to International Classiﬁcation 
of Functioning, Disability and Health) and increase of patients’ quality of life rate 
compared to the initial one (according to EQ-5D questionnaire). Cost-effectiveness 
and cost-utility ratios were calculated. RESULTS: Betaver group included 70 (33.2%) 
patients, Betaserc group—71 (33.6%) patients, and Vestibo group—70 (33.2%) 
patients with moderate vertigo. All patients initially had moderate and severe func-
tional disorders. The proportion of patients without absence of moderate and severe 
functional disorders up to the end of a study was 54% in Betaver group, 57% in 
Vestibo group and 69% in Betaserc group. The average difference between initial 
quality of life rate and the quality of life after the treatment was 19.53, 19.62 and 
22.79 (Betaver, Vestibo and Betaserc groups accordingly). Cost of treatment was 
nearly similar in all groups. The cost-effectiveness ratio according to the criteria “the 
proportion of patients with absence of moderate and severe functional disorders” was 
minimal in Betaserc group (8,088.57) compared to Betaver (10,358.17) and Vestibo 
(8,955.49) groups. The cost-utility ratio according to the criteria “the increase of 
patients’ quality of life rate compared to the initial one” was also minimal in Betaserc 
group (244.89) compared to Betaver (286.4) and Vestibo (260.17) groups. CONCLU-
SIONS: Betaserc seems to be more clinically and economically effective betahistine 
compared to another two medications in treatment of patients with vertigo.
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OBJECTIVES: Opportunity exists for certain hospitalized patients to appropriately 
receive oral (PO) levetiracetam given its bioavailability of 100%. Use of intravenous 
(IV) levetiracetam at our institution had increased and was associated with signiﬁcant 
annual cost. This study aimed to evaluate the use of IV levetiracetam, to identify a 
cost saving opportunity and to project cost savings of potential pharmacist-initiated 
IV-to-PO levetiracetam switches. The goal was to provide information regarding 
medication utilization and cost saving opportunities for hospital administration to 
make informed formulary decisions. METHODS: A retrospective medical chart review 
on 100 randomly selected adult patients receiving at least two doses of IV levetirace-
tam during hospital stays between July 1, 2008 and November 30, 2008 was con-
ducted. Pre-deﬁned eligibility of IV-to-PO levetiracetam switches, costs, doses and 
frequencies were obtained for each patient-day. Only levetiracetam costs were consid-
ered and presented as 2008 average wholesale prices without further adjustments. 
Monte Carlo simulation models were created to predict cost savings, and model 
inputs, parameters and plausible ranges were determined based on real-world data. 
Three scenarios were hypothesized where switches could have been made with “no 
delay,” “12-hour delay” or “24-hour delay” of pharmacist interventions upon iden-
tiﬁcation of eligibility. Probabilistic sensitivity analysis was performed (2,500 trials) 
for each scenario. RESULTS: Among 729 patient-days (from 99 subjects with one 
subject excluded as an outlier), 6.6% made IV-to-PO levetiracetam switches and 
additional 66% were eligible for such switch. With a conservative scenario of 24-hour 
delay, potential cost savings were estimated as follows: mean $512 (SD $714) per 
patient or $69.6 (SD $0.4) per patient-day; median $302 (95% CI $20-$1,661) per 
patient. Of 2,500 estimates, 19.6% could have potential savings of $100–200 
per patient, followed by $0-$100 (15.5%), $200-$300 (14.6%) and $300-$400 
(9.6%). CONCLUSIONS: Pharmacists have potential cost saving opportunities by 
identiﬁcation of eligible IV-to-PO levetiracetam switches.
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OBJECTIVES: An observational study recently showed that combining memantine 
with a cholinesterase inhibitor (ChEI) treatment signiﬁcantly delayed admission to a 
nursing home in patients with Alzheimer’s disease. The objective of this analysis was 
to evaluate the economic impact of the concomitant use of memantine and ChEI on 
time to institutionalization in a Canadian population. METHODS: A cost-utility 
analysis using a Markov model over a 7 years time horizon was performed according 
to a public third party perspective and a societal perspective. The Markov model 
includes the following states: non-institutionalized, institutionalized, and deceased. 
Transition probabilities for institutionalisation were taken from the study by Lopez 
et al., while transition probabilities for death were taken from Canadian survival tables 
and adjusted for mortality rates speciﬁc to Alzheimer’s disease. For the publicly funded 
health care system perspective, costs of medication (ChEI and ChEI + memantine) as 
well as the costs of care provided in the community and in nursing homes were 
considered. For the societal perspective, costs of direct care and supervision provided 
by caregivers were added. RESULTS: From both a societal and a publicly funded 
health care system perspective, the concomitant use of a ChEI and memantine is a 
dominant strategy over the use of a ChEI alone. Thus, the costs associated with the 
use of memantine in combination with a ChEI are lower than those associated with 
the use of a ChEI alone, and the number of Quality-adjusted-life-years (QALYs) 
obtained with a ChEI plus memantine is higher than the number of QALYs obtained 
with a ChEI alone. CONCLUSIONS: The results of this economic evaluation indicate 
that the use of memantine combined with a ChEI to treat Alzheimer’s disease is a 
cost-effective alternative compared to the use of a ChEI alone, both from a health care 
and societal perspective.
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OBJECTIVES: Compare health status, resource utilization, and work productivity 
between caregivers for an adult with epilepsy and a control group of non-caregivers. 
METHODS: Respondents to the 2009 U.S. National Health and Wellness Survey 
(NHWS), a self-administered, internet-based questionnaire of adults, who reported 
providing care for an adult relative with epilepsy, were included in the caregiver group. 
Propensity score methods were used to construct a 5:1 matched control group from 
the general NHWS population, excluding caregivers for any other condition, matched 
on demographics and health characteristics. The caregiver and control groups were 
compared on health status (SF-12v2 Physical Component Summary (PCS) and Mental 
Component Summary (MCS) score) and resource use (number of self-reported hospi-
talizations, ER visits, and physician visits in the past 6 months). Employed caregivers 
were similarly matched to employed controls from the general NHWS respondents 
and compared on work productivity using the Work Productivity and Activity Impair-
ment (WPAI) questionnaire. Statistical analyses included chi-square tests, t-tests, and 
generalized linear models. RESULTS: Of the 75,000 NHWS respondents, 222 self-
reported caregivers were matched to 1,110 controls (p > 0.25 for all included covari-
ates). The caregiver group was 51.8% female with mean (standard deviation) age of 
45.2 (15.4) years. Caregivers had lower mean SF-12v2 PCS scores than controls (43.0 
vs. 46.3, respectively; p < 0.0001) and showed no difference on mean MCS scores 
(44.8 vs. 46.3, respectively; p = 0.090). Caregivers reported signiﬁcantly (p < 0.0001) 
more ER visits (rate ratio (RR) = the ratio of the caregiver group mean to the control 
group mean = 4.15), hospitalizations (RR = 6.44), and provider visits (RR = 1.59) 
than controls. Employed caregivers (n = 124) reported signiﬁcantly (p ≤ 0.0018) higher 
rates of absenteeism (RR = 2.66), presenteeism (RR = 2.08), overall work impairment 
(RR = 2.02), and activity impairment (RR = 1.76) versus controls. CONCLUSIONS: 
Caregivers of adults with epilepsy reported utilizing more health care resources, and 
had lower work productivity, worse physical health status yet no difference in mental 
health status versus non-caregivers.
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OBJECTIVES: Compare multiple sclerosis (MS) severe relapse rates and total direct 
and indirect costs over a two-year study period between employees with MS adherent 
and nonadherent to disease-modifying drugs (DMDs) METHODS: Employees with 
≥1 MS diagnosis (ICD-9-CM: 340.x) and ≥1 DMD pharmacy claim January 1, 2002–
December 31, 2006 were selected from a large US administrative claims database. 
Patients had continuous coverage ≥6 months before (baseline) and ≥24 months after 
(study period) their index date (ﬁrst DMD claim). Adherence was measured using the 
medication possession ratio (MPR) over the 24-month study period. Patients with 
MPR ≥80% were classiﬁed as adherent (n = 448) and those with MPR < 80% were 
classiﬁed as nonadherent (n = 200). Multivariate analyses adjusting for differences in 
baseline characteristics were used to compare severe relapse rates (inpatient or emer-
gency department visit with MS diagnosis) and costs in 2007 dollars between DMD 
adherent and nonadherent patients. Direct medical costs were calculated as reimburse-
ments to providers for medical services and prescription drugs excluding DMDs. 
Indirect costs included disability and medically-related absenteeism costs. RESULTS: 
DMD adherent patients were on average older (43.5 vs. 41.8 years, P = 0.015) and 
more likely to be male (38.6% vs. 26.0%, P = 0.002) compared with nonadherent 
